Search results
FDA panel rejects first MDMA treatment amid deep concerns about flawed trials
NBC News via Yahoo News· 12 hours agoA Food and Drug Administration advisory panel on Tuesday declined to recommend the approval of MDMA,...
FDA warns parents about Crecelac infant formula—what parents need to know about the recall
Motherly via Yahoo News· 24 hours agod3sign/Getty/FDA The FDA has issued an alert warning parents to avoid buying formula from a Texas...
FDA advisers vote against first MDMA therapy to treat PTSD
CNN.com· 13 hours agoAfter hearing presentations from the US Food and Drug Administration, treatment sponsor Lykos...
FDA advisory panel votes against allowing MDMA as PTSD treatment
United Press International via Yahoo News· 11 hours agoThe popular underground drug midomafetamine, also called MDMA and "ecstasy," failed to win an...
FDA Warns Recalled Cookie Dough Company Over “Serious Violations”
IFLScience· 21 hours agoAfter one of its cookie dough products was taken off shelves last year following the discovery it...
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
BioPharma Dive via Yahoo Finance· 18 hours agoA group of independent experts wasn't convinced by clinical trial data from company Lykos...
FDA advisers consider MDMA therapy to treat PTSD
WISN 12 Milwaukee· 22 hours agoA federal advisory committee meets on Tuesday to weigh the risks and benefits of using MDMA, commonly known as ecstasy, as a treatment for post-traumatic...
FDA panel rejects first MDMA-based PTSD treatment
USA Today· 12 hours agoThe panel voted 10-to-1 against the therapy, saying the benefits did not outweigh its risks, while nine of the 11 members said the available data did not...
FDA panel votes against MDMA for PTSD, setting up hurdle to approval
CBS News· 14 hours agoThe committee voted nine against, two in favor, on the question of whether there was enough data to...
FDA panel rejects first MDMA treatment amid deep concerns about flawed trials
NBC NEWS· 14 hours agoThe two votes — one for the treatment’s efficacy and one for its safety, by the agency’s...